AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Myelodysplastic syndrome (MDS) involves abnormal production of blood cells in your bone marrow. MDS is not just one single disease. It is a group of diseases that affect how blood cells are made. In ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

SAN DIEGO — Genetic mutations related to myelodysplastic syndrome occurred significantly more often among people who smoked than nonsmokers, according to study results presented at ASH Annual ...

AbbVie (ABBV) said on Monday that its late-stage trial evaluating its drug Venetoclax in combination with Azacitidine in the ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

If you have MDS, a type of blood cancer called myelodysplastic syndrome, you’re part of a rare group of people with the diagnosis. But research is ongoing. Many clinical trials are seeking new ...

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...

Moreover, Faron Pharmaceuticals is planning to launch a phase 3 trial of bexmarilimab and Vidaza in patients with relapsed/refractory higher-risk myelodysplastic syndrome, pending feedback from the ...

COVID-19 mortality higher for leukemia, myelodysplastic syndrome patients. The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome ...

Myelodysplastic Syndrome Clinical Trials. Clinical research is an essential part of the scientific process that leads to new treatments and better care. Clinical trials can also be a way for patients ...

Find all the latest on myelodysplastic syndrome at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.